Abhishek Kulkarni, MD

Abhishek Kulkarni, MD

Cardiologist, Chief
Cardiology
Accepting new patients
Call for an appointment
or

    About me

    Gender

    Male

    Education & training

    Positions
    Associate Professor
    Vice Chair of Clinical Operations
    Board Certifications
    Internal Medicine
    Cardiology
    Medical School
    Rajiv Gandhi Medical College, Thane, India
    Residency
    Guthrie / Robert Packer Hospital, Sayre, PA – Internal Medicine
    Fellowship
    Guthrie / Robert Packer Hospital, Sayre, PA - Cardiovascular

    Specialties

    Clinical locations

    Locations

    SIU Medicine Heart and Vascular Center | Springfield

    747 N. Rutledge Street Springfield, IL 62702 4th Floor
    Mon - Fri: 8:00 am-4:30 pm

    Hospital privileges

    • HSHS St. John's Hospital, Springfield, IL
    • Memorial Health, Springfield IL

    Featured Publications

    [1] Gupta S.  Singh P.  Verma R.  Kulkarni A.  Jindal G.  Wedge-less V-Shaped Distal Femoral Osteotomy Through Lateral Approach to Correct Valgus Malalignment.  2025 Dec;14(12):103954. 
    PMID: 41541314

    [2] Kaylan KB.  Checkcinco C.  Enriquez JR.  Nargis T.  Elliott E.  Puente AA.  Wang JE.  Walsh M.  Nelson JB.  Kulkarni A.  Muralidharan C.  May SC.  Anderson RM.  Mirmira RG.  Tersey SA.  The G Protein-Coupled Receptor GPR31 Promotes Pro-inflammatory Responses in Pancreatic Islets and Macrophages.  2025 Oct;():. 
    PMID: 41256366

    [3] Dahlberg D.  McKnight B.  Kulkarni A.  Rozumalski L.  Rodriguez F.  Wang Y.  Wagner CR.  Multivalent Tri-Functional T-cell Engagers by Chemically Induced Protein Self-Assembly.  2025 Aug;():. 
    PMID: 40766576

    Clinical trials

    Trial
    Cardiology

    Dal-GenE-2

    Active recruiting
    The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce the occurrence of fatal and non-fatal myocardial infarction in subjects with a documented recent ACS and the AA genotype at variant rs1967309 in the ADCY9 gene.
    Trial
    Cardiology

    Dal-GenE-2

    Active recruiting
    The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce the occurrence of fatal and non-fatal myocardial infarction in subjects with a documented recent ACS and the AA genotype at variant rs1967309 in the ADCY9 gene.